MEDSMEDSHealthcare · Medical Distribution

MEDS Stock Forecast: DataMeds AI, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$1.30
−5.11% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 15 of 100 as at 22 Aug 2026 — in the weakest quartile.

Market cap
$4.2M
Ticker Nerd rank
15 / 100
Median analyst target
Analysts covering
0
Revenue$1.6M−85.6% y/y
Operating income−$6.0M
Net income−$7.7M
Free cash flow−$3.6M
Quarterly, 8 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−12.8%
1M
−59.0%
YTD
−93.5%
1Y
−97.2%
From 52W high
−98.5%
From 52W low
0.0%
$1
$87
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MEDS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores DataMeds AI, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
15 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
99
Size
97
Growth
41
Revisions
25
Volatility
14
Momentum
12
Value
7
Quality
6
Issuance
5

Accruals (99): Reported profit is backed by cash, and the company is not expanding recklessly.

Issuance (5): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MEDS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MEDS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$20$40$60$80Oct 25Jan 26Apr 26Jul 26MEDS

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Recent analyst actionsNewest first
DateFirmActionRatingTarget
1 June 2023EF HuttonAssumesBuy$1.25
16 May 2023EF HuttonMaintainsBuy$1.70$1.25
28 Mar 2023Maxim GroupMaintainsBuy$2.50$1.75
9 Dec 2021EF HuttonInitiatesBuy$4.50
3 Dec 2020National SecuritiesInitiatesBuy
3 Dec 2020National Securities CorporationInitiatesBuy

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MEDS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

MEDS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 24 Aug 2026, DataMeds AI, Inc. returned −97.2% against +19.6% for the S&P 500, dividends included.

MEDS vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Oct 25Jan 26Apr 26Jul 26MEDSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MEDS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

DataMeds AI, Inc. (MEDS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.0×

Cheaper than 76% of US stocks

Price / sales
0.5×

Cheaper than 82% of US stocks

Price / book
−0.2×

Cheaper than 94% of US stocks

EV / EBITDA
−0.6×

Cheaper than 64% of US stocks

Growth & margins
Revenue growth (YoY)
−77.2%

Higher than 3% of US stocks

Earnings growth (YoY)
2304.5%

Higher than 99% of US stocks

Gross margin
10.9%

Higher than 11% of US stocks

Operating margin
−412.7%

Higher than 8% of US stocks

Net margin
−27.5%

Higher than 14% of US stocks

Returns & dividend
Return on equity
813.6%

Higher than 99% of US stocks

Return on assets
−82.9%

Higher than 4% of US stocks

Dividend yield
436.4%

Higher than 99% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

DataMeds AI, Inc. (MEDS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • DataMeds AI, Inc. has a market value of $4.2M and an enterprise value of $34.4M.

  • Revenue in the twelve months to 31 Mar 2026: $14.0M. The latest quarter shrank 77.2% year on year.

  • Net income over the same four quarters: −$76.6M, a −545.7% net margin.

  • Free cash flow in the twelve months to 31 Mar 2026: −$13.7M.

  • Shares outstanding: 2.4M.

  • Trailing P/E: −0.0×; forward P/E: −16.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 436.36%, paying out 0% of earnings.

  • DataMeds AI, Inc. employs 8 people $1.8M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 25 Aug 2026

Data provided by Twelve Data

Peers

MEDS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Distribution
CompanyMarket capTKN rank
MEDSDataMeds AI, Inc.$4.2M
15
SNYRSynergy CHC Corp.$1.5M
53
COSMCosmos Health, Inc.$22.3M
19
SILOSilo Pharma, Inc.*$4.2M
24
NUWENuwellis, Inc.*$4.2M
17
ISPCiSpecimen, Inc.*$4.3M
23
BJDXBluejay Diagnostics, Inc.*$4.1M
20

* Nearest Healthcare names by size — few medical distribution companies of this scale trade in the US universe.

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own DataMeds AI, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MEDS news & analysis

DataMeds AI Reports Second Quarter 2026 Financials and Provides Business Update

Accesswire · 17 Aug 2026positive

DataMeds AI, Inc. (formerly Wellgistics Health) reported Q2 2026 revenues of $1.779 million, up 14% and ahead of management projections, and provided a business update that covered its July 2026 corporate name and ticker change to MEDS, $6.5 million in new June 2026 funding, a pending four-party consolidation of intellectual property tied to the "Health Lives Here" consumer app launch with NFL Alumni Health, a 1:50 reverse split, 49% of shares under lock-up agreements, a Meme Coin token distribution, the KareRx joint venture's EBV addition, and the termination of the Neuritek acquisition.

Why it matters — MEDS watchers would care because this update details the company's turnaround progress, funding, restructuring measures, and near-term product launch plans that define its outlook following the corporate rebrand and NASDAQ listing changes.

DataMEDS AI Announces Its Board of Directors Approved September 9, 2026 as the Payment Date of the Previously Announced Distribution of Dream Bowl Meme Coin I Tokens to Record Holders of Common Stock and other Eligible Equity Securities as of the Record Date of August 7, 2026

Accesswire · 14 Aug 2026neutral

DataMeds AI's board of directors set September 9, 2026 as the payment date for the previously announced distribution of Dream Bowl Meme Coin I tokens to common stockholders and eligible equity security holders as of the record date of August 7, 2026.

Why it matters — This announcement confirms the timing of a non-cash distribution to shareholders that will result in Meds stakeholders receiving 50 Dream Bowl Tokens for each share of common stock held.

DataMeds AI Provides Update on Corexa Health's Pharmacy Division

Accesswire · 12 Aug 2026positive

DataMeds AI announced that its subsidiary Corexa Health's pharmacy division, Corexa Pharmacy, reached milestones including the availability of GLP-1 agonist drugs, integration of online store CorexaRx.com into the Health Lives Here app, and new availability of medical foods Forzet and Galectovid plus supplement Tollovid. July 2026 revenue stabilized above $600,000 as the pharmacy prepares to expand with the Health Lives Here app launch alongside NFL Alumni Health.

Why it matters — A MEDS watcher would care because Corexa Pharmacy is positioned as the centerpiece of company growth for the second half of 2026, and the update indicates stabilizing revenue and expansion catalysts tied to its Health IT and AI platforms.

DataMeds AI Renames Pharmacy Subsidiaries Corexa Pharmacy and Corexa Tech & Hub Under New Corexa Health Division

Accesswire · 10 Aug 2026neutral

DataMeds AI, Inc. (NASDAQ:MEDS) announced that it has completed name changes of its pharmacy and pharmacy-hub subsidiaries, now known as Corexa Pharmacy, LLC and Corexa Tech & Hub, LLC, respectively. Both subsidiaries now operate under the Company's newly renamed pharmacy-focused division, Corexa Health, LLC.

Why it matters — The reorganization signals how DataMeds AI is structuring its pharmacy operations under a unified Corexa Health division, which may matter to investors tracking the Company's corporate framework.

DataMeds AI Reiterates 50:1 Dream Bowl Meme Coin Token to Common Shares Dividend Ratio with an August 7, 2026 Record Date

Accesswire · 6 Aug 2026neutral

DataMeds AI, Inc. (NASDAQ:MEDS) reiterated the August 7, 2026 record date for its 50:1 Dream Bowl Meme Coin token to common shares dividend ratio, and noted the official platform for the tokens is Biconomy.

Why it matters — MEDS watchers would care because the announcement provides a definitive record date and reiterates the terms for the company's token-to-share dividend.

FAQ

Frequently asked questions about MEDS stock

How does Ticker Nerd's model rank MEDS?

As at 22 Aug 2026, DataMeds AI, Inc. ranks 15 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (99 of 100).

What is the MEDS stock forecast for 2030?

No analyst covering DataMeds AI, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MEDS are extrapolating price history, which says nothing about the business.

How has MEDS stock performed over the past year?

DataMeds AI, Inc. returned -97.2% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does DataMeds AI, Inc. do?

Scienture Holdings Inc. is a diversified company engaged in various sectors, including technology and industrial operations.

What is the latest news on MEDS?

The most recent item we track (Accesswire, 17 Aug 2026): "DataMeds AI Reports Second Quarter 2026 Financials and Provides Business Update". DataMeds AI, Inc. (formerly Wellgistics Health) reported Q2 2026 revenues of $1.779 million, up 14% and ahead of management projections, and provided a business update that covered its July 2026 corporate name and ticker change to MEDS, $6.5 million in new June 2026 funding, a pending four-party consolidation of intellectual property tied to the "Health Lives Here" consumer app launch with NFL Alumni Health, a 1:50 reverse split, 49% of shares under lock-up agreements, a Meme Coin token distribution, the KareRx joint venture's EBV addition, and the termination of the Neuritek acquisition.

Company

About DataMeds AI, Inc.

Scienture Holdings Inc. is a diversified company engaged in various sectors, including technology and industrial operations. The primary function of Scienture Holdings Inc. is to invest in and manage a portfolio of businesses that offer innovative solutions and cutting-edge products. With interests spanning multiple industries, the company focuses on fostering growth and operational efficiency in its subsidiary companies. Among its notable features is its strategic investment in technology-driven enterprises that aim to enhance productivity and streamline operations across different market segments. Scienture Holdings Inc. plays a significant role in advancing technological progress while ensuring sustainable development and competitive advantage for its businesses. By maintaining a diverse investment strategy, the company seeks to mitigate risks and maximize potential returns in the dynamic financial markets. Furthermore, Scienture Holdings Inc. contributes to the broader economic landscape by aligning its business operations with emerging market demands and evolving consumer needs, making it a crucial player in the sectors it serves.

CEO Mr. Prashant Patel M.Sc., R.Ph. · 8 employees · United States · https://datamedsai.com